Xlife Sciences AG (XSWX:XLS) Total Assets: CHF517.12 Mil (As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
50 GF Score
Price CHF20.90
GF Value CHF7.30
Valuation Significantly Overvalued
! 13 Warning Signs
View Full Analysis

What is Xlife Sciences AG Total Assets?

Xlife Sciences AG XSWX:XLS -11.06% 50 Total Assets is CHF517.12 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review.

Xlife Sciences AG's Total Assets for the quarter that ended in Dec. 2025 was CHF517.12 Mil.

During the past 12 months, Xlife Sciences AG's average Total Assets Growth Rate was -4.50% per year. During the past 3 years, the average Total Assets Growth Rate was 1.70% per year. During the past 5 years, the average Total Assets Growth Rate was 17.50% per year.

During the past 8 years, Xlife Sciences AG's highest 3-Year average Total Assets Growth Rate was 49.80%. The lowest was 1.70%. And the median was 41.40%.

Total Assets is connected with ROA %. Xlife Sciences AG's annualized ROA % for the quarter that ended in Dec. 2025 was -7.02%. Total Assets is also linked to Revenue through Asset Turnover. Xlife Sciences AG's Asset Turnover for the quarter that ended in Dec. 2025 was -0.00.

Xlife Sciences AG  (XSWX:XLS) Total Assets Explanation

Total Assets is connected with ROA %.

Xlife Sciences AG's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-36.994/( (536.257+517.117)/ 2 )
=-36.994/526.687
=-7.02 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Xlife Sciences AG's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-0.079/( (536.257+517.117)/ 2 )
=-0.079/526.687
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Xlife Sciences AG Total Assets Related Terms

Xlife Sciences AG Total Assets Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Total Assets Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 480.06 490.23 511.99 540.37 517.12

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 511.99 509.86 540.37 536.26 517.12
XSWX:XLS
50GF Score
Xlife Sciences AG XSWX:XLS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Xlife Sciences AG's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=372.359+144.758
=517.12

Xlife Sciences AG's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=372.359+144.758
=517.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of CHF517.12 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Total Assets of CHF517.12 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Total Assets too high?
Xlife Sciences AG's current Total Assets is CHF517.12 Mil. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Total Assets compare to VRTX and REGN?
Xlife Sciences AG's Total Assets of CHF517.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Total Assets is CHF517.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Total Assets is CHF517.12 Mil. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Total Assets is CHF517.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Total Assets: CHF517.12 Mil
  • GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
  • GF Score™: 50/100 with 13 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score

Get the complete analysis for XSWX:XLS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.90
Price
CHF7.30
GF Value